8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Oct 30, 2015)

Filed October 30, 2015For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K on October 30, 2015, to report its financial results for the third quarter ended September 30, 2015. The filing primarily serves to furnish the accompanying press release, which contains the detailed financial performance data. Investors should refer to this press release for insights into the company's revenue, earnings, and any forward-looking guidance provided for the upcoming periods. This report signals a routine update on AbbVie's operational and financial standing. The key information for investors lies within the press release attached as Exhibit 99.1. This document typically includes a breakdown of sales by product and geography, as well as management's commentary on business drivers and strategic initiatives. Investors should pay close attention to the announced results relative to their expectations and any management outlook that could influence future stock performance.

Key Highlights

  • 1AbbVie Inc. announced its third-quarter 2015 financial results on October 30, 2015.
  • 2The 8-K filing primarily serves to furnish the press release detailing these results.
  • 3Investors should consult the attached press release (Exhibit 99.1) for specific financial figures and operational performance.
  • 4The event date reported is October 29, 2015, reflecting the timing of the release of financial information.
  • 5The Chief Financial Officer, William J. Chase, signed the report, underscoring the official nature of the financial disclosure.
  • 6This filing is categorized under Item 2.02 (Results of Operations and Financial Condition) of Form 8-K.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report AbbVie Inc.'s financial results for the third quarter ended September 30, 2015. It does so by furnishing the press release that contains these detailed financial results and operational information.

The specific financial details are contained within the press release dated October 30, 2015, which is attached as Exhibit 99.1 to this 8-K filing. Investors should review this press release for information on revenue, earnings, and other key financial metrics.

The report is signed by William J. Chase, Executive Vice President and Chief Financial Officer of AbbVie Inc., indicating his authorization and oversight of the financial disclosure.

This particular 8-K filing primarily focuses on reporting past financial results. Any strategic information, forward-looking guidance, or commentary on business drivers would be found within the content of the furnished press release (Exhibit 99.1), not within the 8-K document itself.